We are live on
!
Find out more
3C
361 Capital Portfolio holdings
AUM
$213M
1-Year Est. Return
24.26%
This Fund
S&P 500
This Quarter
Est. Return
+35.34%
1 Year Est. Return
+24.26%
3 Year Est. Return
+117.64%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$213M
AUM Growth
-$6.7M
(-3%)
Cap. Flow
-$47.5M
Cap. Flow
% of AUM
-22.27%
Top 10 Holdings %
Top 10 Hldgs %
8.05%
Holding
403
New
118
Increased
30
Reduced
151
Closed
104
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lear
LEA
|
+$1.16M |
| 2 |
Americold
COLD
|
+$1.09M |
| 3 |
Republic Services
RSG
|
+$1.07M |
| 4 |
Howmet Aerospace
HWM
|
+$1.07M |
| 5 |
Intercontinental Exchange
ICE
|
+$911K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Chemed
CHE
|
+$1.96M |
| 2 |
Helen of Troy
HELE
|
+$1.64M |
| 3 |
FTI Consulting
FCN
|
+$1.55M |
| 4 |
Spire
SR
|
+$1.54M |
| 5 |
McKesson
MCK
|
+$1.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.4% |
| 2 | Healthcare | 16.28% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 10.63% |
| 5 | Consumer Discretionary | 9.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Valley National Bancorp
VLY
$7.92B
| $662K | 0.31% |
+84,630
| New | +$650K |
|
177
Collegium Pharmaceutical
COLL
$1.15B
| $661K | 0.31% |
37,779
-5,884
| -13% | -$115K |
|
178
CBIZ
CBZ
$2.41B
| $658K | 0.31% |
27,440
-4,267
| -13% | -$96.8K |
|
|
PPBI
179
DELISTED
Pacific Premier Bancorp
PPBI
| $658K | 0.31% |
30,351
-4,726
| -13% | -$94.7K |
|
180
Lumentum
LITE
$55B
| $651K | 0.31% |
7,999
-9,005
| -53% | -$686K |
|
181
Qualys
QLYS
$4.82B
| $648K | 0.3% |
6,226
-5,336
| -46% | -$559K |
|
|
ZNGA
182
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
| $647K | 0.3% |
67,804
-52,021
| -43% | -$427K |
|
|
NPTN
183
DELISTED
NEOPHOTONICS CORP
NPTN
| $639K | 0.3% |
+71,946
| New | +$620K |
|
184
Cogent Communications
CCOI
$599M
| $630K | 0.3% |
+8,139
| New | +$659K |
|
185
Hilltop Holdings
HTH
$2.26B
| $630K | 0.3% |
34,142
-5,309
| -13% | -$91.2K |
|
|
SCHV
186
Schwab US Large-Cap Value ETF
SCHV
$15.8B
| $629K | 0.29% |
37,653
+4,215
| +13% | +$68.8K |
|
187
Ciena
CIEN
$52.4B
| $626K | 0.29% |
11,558
-7,928
| -41% | -$394K |
|
188
Prestige Consumer Healthcare
PBH
$2.42B
| $622K | 0.29% |
16,547
-2,563
| -13% | -$103K |
|
189
Regenxbio
RGNX
$630M
| $621K | 0.29% |
+16,873
| New | +$629K |
|
|
FRC
190
DELISTED
First Republic Bank
FRC
| $615K | 0.29% |
+5,799
| New | +$595K |
|
191
Omega Healthcare
OHI
$15.3B
| $614K | 0.29% |
+20,657
| New | +$612K |
|
192
State Street SPDR Bloomberg International Treasury Bond ETF
BWX
$1.31B
| $612K | 0.29% |
21,152
-33
| -0.2% | -$930 |
|
193
Electronic Arts
EA
$52.4B
| $611K | 0.29% |
4,625
-26
| -0.6% | -$3.07K |
|
|
EPZM
194
DELISTED
Epizyme, Inc
EPZM
| $607K | 0.28% |
+37,784
| New | +$660K |
|
|
HTLF
195
DELISTED
Heartland Financial USA, Inc.
HTLF
| $606K | 0.28% |
18,113
-2,807
| -13% | -$87.8K |
|
196
Arvinas
ARVN
$534M
| $605K | 0.28% |
18,038
-2,803
| -13% | -$119K |
|
197
Walker & Dunlop
WD
$1.67B
| $605K | 0.28% |
11,898
-1,846
| -13% | -$75.5K |
|
198
United Therapeutics
UTHR
$26.4B
| $602K | 0.28% |
4,977
-1,970
| -28% | -$222K |
|
199
Radian Group
RDN
$5.21B
| $593K | 0.28% |
38,259
-5,935
| -13% | -$87.8K |
|
200
Seagate
STX
$182B
| $593K | 0.28% |
12,246
-3,990
| -25% | -$200K |
|
Similar funds
SIA
PV
RCM
ALIA
TL
RI
SMFS
HF
361 Capital's Q2 2020 Portfolio in Review
As of Q2 2020, 361 Capital held 403 positions worth $213M, down 3% from $220M the previous quarter. Its ten largest holdings account for 8.1% of the portfolio.
361 Capital withdrew a net $47.5M in Q2 2020, closing 104 positions and reducing 151 holdings. Its most notable exit was Chemed, an estimated $1.96M position sold in full.
By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 17% a quarter earlier, followed by Healthcare and Financials.
Against the trend, 361 Capital opened a new position in Lear worth $1.27M.
- 361 Capital's largest Q2 2020 buy was Lear: 11,650 shares worth $1.27M.
- 361 Capital added most to DaVita in Q2 2020, an estimated $427K increase.
- 361 Capital's biggest Q2 2020 reduction was Williams Companies, cutting an estimated $1.41M.
- 361 Capital fully exited Chemed in Q2 2020, selling an estimated $1.96M.
- 361 Capital's ten largest holdings make up 8.1% of its $213M portfolio in Q2 2020.
- 361 Capital opened 118 new positions and closed 104 in Q2 2020.
- 361 Capital's portfolio value fell 3% quarter-over-quarter to $213M.
Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.